The emerging role of thalidomide therapy in HIV-infected patients

Patrick Haslett, Victoria H. Freedman, Gilla Kaplan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Thalidomide is a potent immune response-modifying drug; among its known modes of action is the inhibition of the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha, or 'cachectin'). Clinical studies have shown that thalidomide may ameliorate AIDS-associated weight loss. In addition, clinical evidence indicates a role for thalidomide in the treatment of HIV-associated aphthous ulceration. However, toxicities from thalidomide therapy are more common in patients infected with HIV than in uninfected persons, and patients must be monitored carefully to avoid the drug's well-known teratogenic effects.

Original languageEnglish (US)
JournalInfections in Medicine
Volume14
Issue number5
StatePublished - May 1997
Externally publishedYes

Fingerprint

Thalidomide
HIV
Tumor Necrosis Factor-alpha
Therapeutics
Pharmaceutical Preparations
Weight Loss
Acquired Immunodeficiency Syndrome
Cytokines

Keywords

  • AIDS wasting syndrome
  • Aphthous ulcers
  • Immunomodulation
  • Thalidomide
  • Tumor necrosis factor-alpha

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

The emerging role of thalidomide therapy in HIV-infected patients. / Haslett, Patrick; Freedman, Victoria H.; Kaplan, Gilla.

In: Infections in Medicine, Vol. 14, No. 5, 05.1997.

Research output: Contribution to journalArticle

@article{2ac014a44354457ab0b55dd04a33ad16,
title = "The emerging role of thalidomide therapy in HIV-infected patients",
abstract = "Thalidomide is a potent immune response-modifying drug; among its known modes of action is the inhibition of the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha, or 'cachectin'). Clinical studies have shown that thalidomide may ameliorate AIDS-associated weight loss. In addition, clinical evidence indicates a role for thalidomide in the treatment of HIV-associated aphthous ulceration. However, toxicities from thalidomide therapy are more common in patients infected with HIV than in uninfected persons, and patients must be monitored carefully to avoid the drug's well-known teratogenic effects.",
keywords = "AIDS wasting syndrome, Aphthous ulcers, Immunomodulation, Thalidomide, Tumor necrosis factor-alpha",
author = "Patrick Haslett and Freedman, {Victoria H.} and Gilla Kaplan",
year = "1997",
month = "5",
language = "English (US)",
volume = "14",
journal = "Infections in Medicine",
issn = "0749-6524",
publisher = "CMP Healthcare Media LLC",
number = "5",

}

TY - JOUR

T1 - The emerging role of thalidomide therapy in HIV-infected patients

AU - Haslett, Patrick

AU - Freedman, Victoria H.

AU - Kaplan, Gilla

PY - 1997/5

Y1 - 1997/5

N2 - Thalidomide is a potent immune response-modifying drug; among its known modes of action is the inhibition of the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha, or 'cachectin'). Clinical studies have shown that thalidomide may ameliorate AIDS-associated weight loss. In addition, clinical evidence indicates a role for thalidomide in the treatment of HIV-associated aphthous ulceration. However, toxicities from thalidomide therapy are more common in patients infected with HIV than in uninfected persons, and patients must be monitored carefully to avoid the drug's well-known teratogenic effects.

AB - Thalidomide is a potent immune response-modifying drug; among its known modes of action is the inhibition of the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha, or 'cachectin'). Clinical studies have shown that thalidomide may ameliorate AIDS-associated weight loss. In addition, clinical evidence indicates a role for thalidomide in the treatment of HIV-associated aphthous ulceration. However, toxicities from thalidomide therapy are more common in patients infected with HIV than in uninfected persons, and patients must be monitored carefully to avoid the drug's well-known teratogenic effects.

KW - AIDS wasting syndrome

KW - Aphthous ulcers

KW - Immunomodulation

KW - Thalidomide

KW - Tumor necrosis factor-alpha

UR - http://www.scopus.com/inward/record.url?scp=16944367538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16944367538&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:16944367538

VL - 14

JO - Infections in Medicine

JF - Infections in Medicine

SN - 0749-6524

IS - 5

ER -